Business
Eli Lilly is about to report earnings. Here's what to expect
Eli Lilly is slated to report third-quarter earnings and revenue, which will likely be fueled by its obesity drug Zepbound and diabetes counterpart Mounjaro.
- Published
- (1 h ago)
- Outlet
- CNBC Top News
- Section
- Business
- Length here
- Headline and 24-word snippet. The full article is at the source.
More from CNBC Top News and around the same time
U.S. worker job engagement hits lowest level since 2011, new Gallup poll findsGallup finds U.S. worker engagement on the job sinking to a level not seen since 2011, with remote and hybrid employees and AI primary factors.Alphabet earnings miss reflects first real sign that AI is taking a bite out of searchWall Street hammered Alphabet for an earnings miss that included weaker-than-expected revenue out of the company's core business.Restaurant Brands reports mixed results as Burger King's U.S. turnaround shows signs of successBurger King's U.S. restaurants outperformed, while Popeyes disappointed.Merck tops quarterly estimates, hikes profit outlook as new form of Keytruda shows strengthMerck's immunotherapy Keytruda, including a newer injectable form of the drug, showed stronger-than-expected sales.European Central Bank President Lagarde to stand down in FebruraryCNBC Top News, published October 29, 2026It's a 'socialist' bank — and North Dakota Republicans love itDemocratic socialist candidates have held up North Dakota's state-owned bank as a model to emulate.This page holds the headline and a short snippet as published by CNBC Top News, whose feed they came from. The story itself, the photography and the rights stay with them, and the button above goes straight to their site. We keep this page so the headline has a stable address and a record of when it ran.
